Loading...
•
Mar 31, 2023
Mimedx Q1 2023 Earnings Report
Reported net sales growth and improved financial profile.
Key Takeaways
MiMedx Group, Inc. announced its Q1 2023 results, featuring a 21.7% increase in net sales to $71.7 million compared to the prior year period. The company reported a net loss of $5.0 million and an Adjusted EBITDA of $5.5 million, driven by demand for new products and improved cost controls.
Net sales increased by 21.7% year-over-year to $71.7 million.
Net loss improved to $5.0 million, compared to $10.5 million in the prior year period.
Adjusted EBITDA was $5.5 million, a substantial increase from the prior year period's loss of $1.7 million.
Gross margin improved sequentially, reversing the trend from 2022.
Forward Guidance
The Company anticipates sales growth in the low double-digits annually, driven by new product uptake, demand across service sites, and sales in Japan. They aim for a Wound & Surgical segment contribution margin at or above 30% of segment net sales and corporate expenses below 20% of sales.
Positive Outlook
- Continued uptake of new products
- Solid demand across its sites of service
- Ramping contributions from sales in Japan
- Wound & Surgical segment contribution margin at or above 30% of segment net sales
- Corporate expenses as a percentage of sales below 20%
Challenges Ahead
- Future sales are uncertain and are affected by competition and access to customers
- Patient access to healthcare providers
- The reimbursement environment
- The results of scientific research are uncertain and may have little or no value
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...